Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Olema Pharmaceuticals, Inc. entered into Purchase Agreement with the purchasers named therein (the "Purchasers") valued at approximately $130 million (effective 2023-09-05).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the purchasers named therein (the "Purchasers")
- Value
- approximately $130 million
- Effective
- 2023-09-05
Exact text from the filing
On September 5, 2023, Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), which provides for the private placement of 13,211,381 shares (the “Shares”) of the Company’s common stock (the “Common Stock”) at $9.84 per share (such transaction, the “Private Placement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Olema Pharmaceuticals, Inc. entered into Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the "Bank") valued at up to $50 million (effective 2023-09-05).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the "Bank")
- Value
- up to $50 million
- Effective
- 2023-09-05
Exact text from the filing
On September 5, 2023, the Company entered into a Loan and Security Agreement (the “Loan Agreement”), by and between the Company, as borrower, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Bank”). The Loan Agreement provides for a four-year senior secured Loan facility in an aggregate principal amount of up to $50 million (the “Loan Facility”), of which $25 million will be available upon the receipt by the Company of $100 million in gross proceeds from the Private Placement, and up to $25 million of which may be made available upon approval of the Bank in its discretion.
View on SEC.gov